Digitalis-like compounds (DLCs), or cardiac glycosides, are produced and sequestered by certain plants and animals as a protective mechanism against herbivores or predators. Currently, the DLCs digoxin and digitoxin are used in the treatment of cardiac congestion and some types of cardiac arrhythmia, despite a very narrow therapeutic index. P-glycoprotein (P-gp; ABCB1) is the only known ATPdependent efflux transporter that handles digoxin as a substrate. I306A, F343A, F728A , T945A, and L975A abolished NMQ transport activity of P-gp. For the other mutants, the apparent affinities for six DLCs (cymarin, digitoxin, digoxin, peruvoside, proscillaridin A, and strophanthidol) were determined. The affinities of digoxin, proscillaridin A, peruvoside, and cymarin for mutants F336A and I340A were decreased two-to fourfold compared with wild type, whereas that of digitoxin and strophanthidol did not change. In addition, the presence of a hydroxyl group at position 12β seems to reduce the apparent affinity when the side chain of Phe 336 and Phe 942 is absent. Our results showed that a δ-lactone ring and a sugar moiety at 3β of the steroid body are favorable for DLC binding to P-gp. Moreover, DLC inhibition is increased by hydroxyl groups at positions 5β and 19, whereas inhibition is decreased by those at positions 1β, 11α, 12β, and 16β. The understanding of the P-gp-DLC interaction improves our insight into DLCs toxicity and might enhance the replacement of digoxin with other DLCs that have less adverse drug effects.
Digitalis-like compounds (DLCs), or cardiac glycosides, are made by certain plants (e.g., Apocynaceae family) and animals (e.g., Bufonidae family) (Hallbook et al., 2011; Lopez-Lazaro, 2007) . These toxic metabolites are produced and sequestered as a protective mechanism against herbivores or predators, and plant extracts were used as arrow poison by humans. DLCs have been employed therapeutically for the treatment of congestive heart failure for many years. Digoxin is the most prescribed DLC, and its use is characterized by a narrow therapeutic plasma concentration range (0.8-2 µg/l). Above 3 µg/l symptoms of toxicity occur, such as fatigue, nausea, vomiting, anorexia, visual disturbances, ventricular fibrillation, and ultimately death (Vivo et al., 2008) . Digoxin toxicity has been ranked as the second cause of drug-related hospital admissions in the United States (Abad-Santos et al., 2000; Haynes et al., 2009 ). The drug is excreted via renal clearance and intestinal secretion. Comedication with drugs such as verapamil, nifedipine, nitrendipine, propafenone, amiodarone, quinidine, cyclosporin, and itroconazole is known to increase digoxin in plasma up to toxic levels due to inhibition of transporters in the excretory organs (Belz et al., 1983; Pauli-Magnus et al., 2001; Verschraagen et al., 1999; Woodland et al., 1998) .
As digoxin interaction with P-glycoprotein (P-gp; MDR1/ ABCB1) substrates is one of the key factors in its toxicity, transport via P-gp has been extensively studied (de Lannoy and Silverman, 1992) and there is ample evidence that inhibition of P-gp transport increases the digoxin plasma levels and thereby its toxicity (Boyd et al., 2000; Englund et al., 2004; Lowes et al., 2003; Shoaf et al., 2011; Westphal et al., 2000) . Moreover, numerous studies have shown that P-gp polymorphisms influence digoxin plasma concentration. The synonymous polymorphisms, C3435T (Ile1145Ile) and G2677C (Ala893Pro), are the alleles that have been shown to increase orally administered digoxin levels in plasma in German population. On the other hand, there are also studies that reported that there is no association between these two polymorphisms and the digoxin plasma levels in Polish Caucasian and Japanese populations (Hoffmeyer et al., 2000; Johne et al., 2002; Kurzawski et al., 2007; Sakaeda et al., 2001) . It seems that P-gp polymorphisms might influence the digoxin plasma levels population dependently. P-gp is located mainly in tissues with a barrier function like intestine (brush border membrane of enterocytes), kidney (brush border membrane of proximal tubular cells), and lumenal side of brain capillary endothelial cells (Jutabha et al., 2010; Pauli-Magnus et al., 2001) . P-gp is an ATP-dependent drug pump that mediates efflux of a broad range of compounds. It is a 1280 amino acid long plasma membrane glycoprotein that consists of two halves, each of which begins with a transmembrane domain (TMD) containing six transmembrane helices (TM), followed by a nucleotide-binding domain (NBD) (Loo et al., 2009) . The intracellular NBDs exhibit ATPase activity that is necessary for substrate translocation, whereas the drug-binding pocket is located between the interface of two TMDs (Loo et al., 2007 (Loo et al., , 2008 (Loo et al., , 2009 . Recently, the crystal structure of mouse P-gp (ABCB1), which has 87% sequence identity to human P-gp, has been determined in the presence of cyclic peptide inhibitors (Aller et al., 2009; Ravna et al., 2009) . Several amino acids involved in binding of these inhibitors were previously identified in mutagenesis studies as amino acids that play a role in substrate binding (Loo et al., 2006a (Loo et al., , 2007 .
In addition to digoxin, a number of DLCs have been discovered that might also have therapeutic value in treatment of heart disease. These compounds all have the same mechanism of action as digoxin, but they have a different pharmacokinetic profile, which could be more favorable for treatment. Because P-gp activity influences digoxin plasma levels, identification of DLCs that have less interaction with P-gp could be valuable. Until now, only digoxin, digitoxin, and ouabain have been studied in P-gp transport assays, but knowledge about their P-gp-binding site is lacking (Cavet et al., 1996; Pauli-Magnus et al., 2001; Sharom, 1995) .
In the present study, we have expanded the knowledge about DLC interaction with human P-gp by investigating the inhibitory effect of 15 different DLCs (Fig. 1 ) on P-gp-mediated transport of N-methyl-quinidine (NMQ) into human P-gp-containing membrane vesicles. NMQ is actively transported by P-gp in a vesicular transport assay (Hooiveld et al., 2002) . Our experiments showed that DLCs such as digitoxin, proscillaridin A, peruvoside, cymarin, and strophanthidol inhibited P-gp transport activity. To further understand the interaction of DLCs and NMQ with human P-gp, amino acids were mutated that could play a key role in the binding and translocation of drugs. Based on the description of drug-binding amino acids in crystallized mouse P-gp (Aller et al., 2009) in TM11, and Leu 975 and val 982 in TM12 of human P-gp for mutation to alanine, and thereby investigated the role of these amino acids in transport of NMQ in the presence and absence of different DLCs. Removal of the side chain resulted in loss of NMQ transport activity of five human P-gp mutants: I306A, F343A, F728A, T945A, and L975A, which seem to have key role in the transport of NMQ. However, transport activity was preserved in L65A, I306A, I340A, F942A, and V982A. These mutants were further analyzed to elucidate their role in DLC binding.
MATErIALs AND METHODs
Materials. Dulbecco's Modified Eagle's Medium (DMEM) and Gluta-MAX-11 were purchased from Invitrogen (Breda, The Netherlands). [
3 H]-NMQ (specific activity, 76.7 Ci/mmol) and unlabeled NMQ were purchased from Solvo Biotechnology (Szeged, Hungary). The Bac-to-Bac system, Cellfectin II reagent, and Grace's insect cell medium were purchased from Invitrogen. The primers for the mutagenesis were produced by Biolegio (Nijmegen, The Netherlands). The plasmid purification midiprep kit was from Genomed (Löhn, Germany). Protein concentration was measured with an assay kit from Bio-Rad Laboratories (Veenendaal, The Netherlands). DLCs (convallatoxin, cymarin, digitoxigenin, digitoxin, digoxigenin, digoxin, dihydroouabin, gitoxigenin, oubagenin, ouabain, peruvoside, strophanthidin, strophanthidol, bufalin, and proscillaridin A) were purchased from Sigma (Zwijndrecht, The Netherlands). The mouse monoclonal antibody against P-gp, C219, and the secondary antibody, fluorescent goat anti-mouse IgG antibody IRDye 800, were purchased from Abcam (Cambridge, United Kingdom) and Rockland immunochemicals for research (Heerhugowaard, The Netherlands), respectively.
Cell culture. HEK293 cells were grown in 182-cm 2 flasks using DMEM + Gluta MAX-1 supplemented with 10% fetal calf serum at 37°C under 5% CO 2 humidified air. The cells were recultured twice a week when they were 70-80% confluent in a ratio of 1:4.
Generation of human P-gp baculovirus. Full-length human P-gp cDNA, according to Genbank accession number NM_000927, was cloned into the gateway entry clone. The gateway system was used to clone the constructs in to a VSV-G-improved pFastBacDual vector and transduce mammalian cells as described before (El-Sheikh et al., 2008) . The Bac-to-Bac system was used to produce human P-gp baculovirus as described in manual (Invitrogen).
Site-directed mutagenesis. A site-directed PCR was performed using pENTR-P-gp vector as template and PfuUltra II fusion HS as DNA polymerase. Ten different P-gp mutants were produced: L65A, I306A, F336A, I340A, F343A, F728A, F942A, T945A, L975A, and V982A and all mutations were confirmed by sequencing of full-length P-gp cDNA.
Transduction of HEK 293 cells with P-gp and mutant expression vectors.
HEK293 cells were cultured in 182-cm 2 flasks, 13 ml of which were seeded in 500-cm 2 triple flasks (Sanbio, Uden, The Netherlands) at 85-95% confluency. After 24 h, the culture medium was removed and 25 ml of fresh medium and 10 ml of baculovirus preparations of enhanced yellow fluorescent protein (eYFP), P-gp, or P-gp mutants were added. These cells were incubated at 37°C for 20 min and finally, 40 ml of medium was added to them. Sodium butyrate was added to the cells 6 h after transduction up to a final concentration of 5mM, and the cells were harvested 3 days later.
Isolation of membrane vesicles and protein analysis. Transduced cells were harvested by centrifugation at 3500 × g for 20 min. The isolation of membrane vesicles was performed according to previously described method (El-Sheikh et al., 2008) . Briefly, the pellets were resuspended in ice-cold hypotonic buffer supplemented with protease inhibitors. The lysed cells were centrifuged at 100,000 × g at 4°C for 30 min. The pellet was homogenized in ice-cold TS buffer (10mM Tris-HEPES and 250mM sucrose, pH 7.4) supplemented with the protease inhibitors using a tight-fitting Dounce homogenizer for 25 strokes. After centrifugation at 4000 × g, 4°C for 20 min, the supernatant was centrifuged at 100,000 × g at 4°C for 60 min. The membrane pellet was resuspended in ice-cold TS buffer and passed through a 27-gauge needle 25 times to form vesicles. Protein concentration was measured by using the Bio-Rad protein assay kit (Bio-Rad). Crude membrane vesicles were frozen in liquid nitrogen and stored at −0°C until use.
Western blot analysis. The preparations of the membrane vesicle (18 µg) were solubilized in SDS-PAGE sample buffer and separated on SDS containing 7.5% acrylamide. The protein samples were blotted on nitrocellulose membrane using iBlot dry blotting system (Invitrogen). P-gp and mutant P-gp were detected by monoclonal anti-human P-gp mouse serum antibody. β-Actin was detected by monoclonal anti-human β-actin mouse serum antibody as a loading control in eYFP and P-gp vesicle preparations. The fluorescent goat anti-mouse IgG antibody IRDye 800 was used as a secondary antibody and Odyssey infrared imaging system (Li-Cor Biosciences, Lincoln, NE) was used to visualize signals. ure [ (2011) . In summary, the vesicles preparations (7.5 µg) were prewarmed at 37°C and added to TS buffer containing 10mM MgCl 2 , 4mM ATP, and 0.1µM [ 3 H]-NMQ at a final volume of 30 µl. The samples were transferred to ice to stop the reaction using 150 µl of ice-cold TS buffer. A Multiscreen HTS Vaccum Manifold filtration device (Millipore, Etten-Leur, The Netherlands) was applied to filter the diluted mixture through 0.65-µm pore, 96-well Multiscreen HTS FB (glass fiber) filters (Millipore) that were preincubated with TS buffer. After aspiration of the samples, the filters were washed with TS buffer twice. Subsequently, 2 ml scintillation fluid was added to each sample followed by liquid scintillation counting. In all experiments, net ATP-dependent transport was calculated by subtracting values measured in presence of adenosine monophosphate (AMP) from the values measured in presence of ATP. All experiments were performed in triplicates and were repeated with three different preparations of membrane vesicles.
Vesicular transport assay. A rapid filtration technique was applied to meas

Vesicular inhibition assays.
To investigate the effect of different DLCs on P-gp-mediated NMQ transport, the previously described assay was performed in the presence of different DLCs. All DLCs were dissolved in dimethyl sulfoxide (DMSO) and were diluted to a final concentration of 100 and 1000µM in the incubation medium. Further, 1% DMSO (vehicle control) and 100µM NMQ were used as the negative and positive control for inhibition, respectively. The inhibitory effect of digoxin, digitoxin, proscillaridin A, peruvoside, strophanthidol, cymarin, and bufalin on wild-type and mutant P-gp-mediated NMQ transport was investigated further by applying different concentrations of these compounds ranging from 1 to 1000µM.
Kinetic analysis. To determine K m and V max values for P-gp-mediated NMQ transport, membrane vesicles (7.5 µg protein) were incubated with increasing concentration of NMQ in the presence of 20nM [ DLCs have different substitutuents on the steroid ring, which is the core structure. (B) Steroid ring structure of DLCs illustrating carbon numbers, sugar moiety position on C-3 (R1), and lactone ring position on C-17 (R2). Based on the struture of DLCs, one of the illustrated sugars is located on C-3. The cardenolides and bufadienolides contain γ-butyrolactone (γ-lactone) and δ-valerolactone (δ-lactone) at the 17 position, respectively. γ-Lactone is saturated in dihydro forms of cardenolides such as dihydroouabain. The inhibition pattern of DLCs (1000µM) on P-gp-mediated NMQ tranport is shown as 25-50% (+), 50-75% (++), 75-90% (+++), and 90-100% (++++) inhibited transport by P-gp. 504 GOZALPOUR ET AL.
x and y indicate log inhibitor concentration and uptake versus control, respectively. Curve fitting was done by using GraphPad Prism software version 5 (GraphPad Software Inc., San Diego, CA). Statistical differences were tested by one-way ANOVA followed by Dunnett's post hoc multiple comparison. A p < 0.05 was considered significant.
rEsuLTs
Expression of P-gp
Immunoblot analysis performed on membrane vesicles from HEK293 cells overexpressing P-gp demonstrated successful expression of P-gp at approximately 170 kDa (Fig. 2A) . The negative control, consisting of membrane vesicles from eYFPoverexpressing HEK293 cells, showed no expression of P-gp.
Kinetics of P-gp-Mediated NMQ Transport
To determine the kinetic characteristics of P-gp in our vesicle assay, we determined the time and concentration dependency of P-gp-mediated NMQ transport. Time-dependent NMQ transport activity at 100nM was linear up to 1 min (Fig. 2B) . Next, we measured concentration-dependent uptake of NMQ into membrane vesicles (Fig. 2C) . ATP-dependent NMQ transport reached a maximum activity (V max ) of 901 ± 51.3 pmol/mg protein/min (mean ± SEM). The K m of NMQ transport via P-gp was 2.2 ± 0.48μM, which is somewhat lower than that reported previously for P-gp expressed in Sf21 insect cells (15μM) (Hooiveld et al., 2002) .
Effect of DLCs on P-gp-Mediated NMQ Transport
Two concentrations (100 and 1000μM) of 15 DLCs were used to determine the P-gp-DLC interaction. NMQ (100nM) transport activity of P-gp (43.7 ± 3.8 pmol/mg protein/min) was set at 100% and 100µM unlabeled NMQ was used as a positive control (Fig. 3) . The large difference between the substrate concentration (100nM) and the DLC concentration (100 and 1000μM) ascertain that most inhibitory effects will be observed. Cymarin, digitoxin, digoxin, peruvoside, strophanthidol, bufalin, and proscillaridin A inhibited P-gp-mediated transport of NMQ by 70-100% at 1000μM. At 100µM, the most potent P-gp inhibitors, digitoxin and proscillaridin A, inhibited NMQ transport by 91 and 97%, respectively. The DLC inhibitor potency of P-gp-mediated NMQ transport could be categorized as follows: digitoxin = proscillaridin A > digoxin = peruvoside = strophanthidol = bufalin > convallatoxin = digitoxigenin = cymarin > strophanthidin. Digoxigenin, dihydroouabain, gitoxigenin, ouabagenin, and ouabain did not significantly inhibit P-gp-mediated NMQ transport.
DLC Concentration-Dependent Inhibition of P-gp-Mediated NMQ Transport
The inhibitory potencies of cymarin, digitoxin, digoxin, peruvoside, proscillaridin A, and strophanthidol were quantified at 100nM NMQ (Fig. 4) . The net NMQ transport by P-gp in the presence of increasing concentrations of DLCs was plotted and analyzed by nonlinear regression. The IC 50 values of the most potent P-gp inhibitors, digitoxin and proscillaridin A, were 9 and 25µM, respectively, whereas, cymarin, digoxin, peruvoside, and strophanthdiol had 10-fold higher IC 50 values of 432, 188, 214, and 242µM, respectively.
Functional Expression of P-gp Mutants
To elucidate the DLC-binding site of P-gp, 10 mutants of human P-gp were constructed and expressed in HEK293 cells (Fig. 5) . All the indicated amino acids were replaced by alanine to remove the side chain of the residue (L65A, I306A, F336A, I340A, F343A, F728A, F942A, T945A, L975A, and V982A). First, the expression levels of wild-type and mutant enzymes were investigated by Western blot analysis (Fig. 5A) . Although, some variation was observed between the different batches, the , and concentration-dependent uptake of (NMQ) (C) by membrane vesicles isolated from HEK293 cells overexpressing human P-gp (▪) and eYFP (•). Top (A) represents membrane vesicles (18 µg) prepared from HEK293 cells overexpressing human P-gp and eYFP as the control. β-Actin was used as loading control for each vesicle preparation. Top (B) shows NMQ uptake of membrane vesicles (7.5 µg protein) incubated with 100nM NMQ at the indicated time points. Bottom (C) represents ATP-dependent NMQ uptake in the presence of increasing concnetration of NMQ. In (B) and (C), the mean values (pmol/mg protein/min) ± SEM of three vesicle preparations are shown.
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average expression of the mutants was similar to that of wildtype P-gp. Next, we determined the NMQ transport activity of these P-gp mutants (Fig. 5B) . NMQ transport activity of mutants L65A, F336A, I340A, F942A, and V982A as compared with wild-type P-gp ranged from 60 to 150%, whereas NMQ transport activity of I306A, F343A, F728A, T945A, and L975A varied between 8 and 30%.
Concentration-Dependent Inhibition of DLCs on NMQ Transport by P-gp Mutants
The inhibitory potency of DLCs on NMQ uptake by selected P-gp mutants was analyzed. For this purpose, the DLCs that were used to determine the concentration-dependent inhibition of P-gp-mediated NMQ transport were selected (Fig. 4) . In addition, five P-gp mutants (L65A, F336A, I340A, F942A, and V982A), for which NMQ transport activity was at least 50% of wild-type transport, were selected. NMQ transport of these mutants was plotted in the absence and presence of increasing concentrations of cymarin, digitoxin, digoxin, peruvoside, strophanthidol, and proscillaridin A (Fig. 6) . The IC 50 value of each compound was determined for wild-type and P-gp mutants using nonlinear regression analysis ( ), digoxin (not significant), peruvoside, and proscillaridin A, whereas it hardly affected the affinity for digitoxin (1.6-2.0) or strophanthidol (0.6-1.1) (Fig. 6) . F942A seems to affect the digoxin binding (3.0), although not significantly.
DIsCussION
DLCs like digoxin are used for treatment of heart failure, however, its narrow therapeutic window limits a safe application in therapy. P-gp transport is known to be a determinant of Fig. 3 . Inhibitory effect of different DLCs on NMQ (100nM) transport by P-gp. Dimethyl sulfoxide (Ctrl) and cold NMQ (100µM) were used as controls. Fifteen DLCs of 100 and 1000µM were used in this assay. The transport activity of P-gp for 100nM NMQ (43.7 ± 3.8 pmol/mg protein/ min) in the presence of DMSO was set at 100%. Each bar represents mean ± SEM value of three experiments. Each mean value was compared with Ctrl (DMSO) using one-way ANOVA, followed by a Dunnett's post hoc test, *p < 0.05, **p < 0.01, ***p < 0.001.
Fig. 4.
Inhibition of P-gp-mediated NMQ transport by DLCs. Membrane vesicles were incubated with 100nM NMQ in the presence of cymarin (A), digitoxin (B), digoxin(C), peruvoside (D), proscillaridin A (E), and strophanthidol (F) at concentrations ranging from 0 to 1000µM. The highest specific NMQ transport (pmol/mg protein/min) for each vesicle membrane preparation in the presence of increasing concentrations of cymarin, digitoxin, digoxin, peruvoside, proscillaridin A, and strophanthidol were 34.4 ± 3.3, 37.7 ± 3.5, 34.4 ± 3.5, 36.2 ± 6.8, 37.4 ± 7.7, and 39.2 ± 4.6 (mean ± SEM), respectively. These values were set at 100% for each vesicle membrane preparation and the percentage of mean values ± SEM of three to five preparations are shown.
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the plasma level of digoxin, and therefore drug-drug interactions with substrates or inhibitors of P-gp further complicate digoxin therapy. In this study, we investigated which structural features are important for interaction of DLCs with P-gp, and explored whether other DLCs could also interact with P-gp.
We expressed human P-gp in HEK293 cells using the mammalian baculovirus expression system described previously (El-Sheikh et al., 2008; Shukla et al., 2012) and determined NMQ transport into vesicles. The transport of NMQ could be inhibited by digitoxin, proscillaridin A, digoxin, peruvoside, strophanthidol, and bufalin, whereas the other DLCs did hardly (convallatoxin, cymarin, digitoxigenin, and strophanthidin) or not (digoxigenin, dihydroouabain, gitoxigenin, ouabagenin, and ouabain) inhibit this transport. Comparison of the inhibitory capacity of the different DLCs could provide information about which DLC substituent is important for binding to P-gp.
The sugar group at position 3β apparently can improve binding of most DLCs to P-gp. Digitoxin and digoxin are stronger inhibitors than digitoxigenin and digoxigenin, illustrating that the tri-D-digitoxose sugar moiety improves inhibitory potency (Fig. 1 ). In addition, proscillaridin A, which has a L-rhamnose group at the 3β position, has a higher inhibitory potency than bufalin, which lacks a sugar group. However, addition of L-rhamnose group at 3β does not necessarily assign a good inhibitory capacity to the compound, because in the case of ouabain and ouabagenin, the sugar-containing ouabain had no inhibitory effect. From our study, it is not clear if different sugar groups contribute to the observed variation in DLC inhibitory potencies. The only difference between convallatoxin and cymarin is the sugar group (L-rhamnose vs. D-cymarose, respectively) and this apparently did not result in a different inhibitory potency.
The tested DLCs contain hydroxyl groups at positions 1β, 5β, 11α, 12β, 14, 16β, and 19. In this series, the hydroxyls at positions 1β and 11α and at positions 5β and 19 are always present together, therefore we cannot come to a conclusion on the individual contribution of hydroxyl groups at these positions (Fig. 1) . The presence of both hydroxyl groups at positions 1β and 11α diminishes the inhibitory potency (strophanthidol vs. ouabagenin), whereas when located at positions 5β and 19, inhibitory potency is increased (strophanthidol vs. gitoxigenin). In addition, the presence of the 12β hydroxyl group (digitoxigenin vs. digoxigenin and digitoxin vs. digoxin) and a hydroxyl group at 16β position (gitoxigenin vs. digitoxigenin) lowers the inhibitory potency. Comparing strophanthidin with strophanthidol shows that a hydroxyl at position 19 is favorable for binding over a carbonyl at this position. Comparing convallatoxin with ouabain shows that the absence of hydroxyl groups at 1β and 11α results in a stronger inhibition than the replacement of an oxygen by a hydroxyl at position 19. It can be concluded that all hydroxyls discussed above, lower the inhibitory potency of DLCs, except for the combination at positions 5β and 19.
In this study, we cannot state that saturation of the lactone ring influences the binding affinity significantly (ouabain vs. dihydroouabain). On the other hand, a δ-lactone ring increases inhibitory potency over a γ-lactone ring (digitoxigenin vs. bufalin).
Overall, the structure-function relationships observed indicate that a DLC with a sugar moiety at 3β, only hydroxyls at 5β, 14, and 19, and a δ-lactone ring should have a very high inhibitory capacity for P-gp. However, such a relationship might be too simple considering the polyspecific binding properties of P-gp as shown in the crystal structures of P-gp in complex with two stereoisomers of cyclic hexapeptide inhibitors (Aller et al., 2009) , whereas only one R stereoisomer (cyclictris-(R)-valineselenazole [QZ59-RRR]) was bound, two S stereoisomers (cyclic-tris-(S)-valineselenazole [QZ59-SSS]) were bound in the binding pocket. Moreover, the location of these binding sites was not comparable.
To obtain a better indication of the precise binding site of the DLCs, we removed the side chains (mutation to Ala) of 10 amino acids. We selected these mutants from the description of Mus musculus P-gp (Aller et al., 2009 .86 pmol/mg protein/min) was set at 100%. Mean ± SEM of four different vesicle preparations are shown. The transport activity of each mutant was compared with wild-type P-gp using one-way ANOVA, followed by a Dunnett's post hoc test, *p < 0.05, **p < 0.01.
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The function of these P-gp mutants was characterized by their NMQ transport activity. NMQ is a P-gp substrate that is very well transported in vesicular transport assays (Hooiveld et al., 2002) . It was found that P-gp mutants could be divided in two groups. The first group of mutants (I306A, F343A, F728A, T945A, and L975A) exhibited a significantly lower NMQ transport activity (8-30% of wild-type P-gp). Other studies, using site-directed mutagenesis indicated that Ile 306 , Phe 727 , Thr 945 , and Leu 975 are also important for verapamil binding (Aller et al., 2009 ). In addition, Phe 343 was shown to play a role in binding of P-gp substrates such as vinblastin, cyclosporine A, and colchicine (Loo et al., 2009) . In several studies, all these amino acids have been shown to play a key role in P-gp substrate transport (Lee et al., 2010; Loo and Clarke, 1996 , 1999a , 1999b Loo et al., 2006b; 2007; Tran et al., 2005) . The reduced transport activity we observed indicates that these residues are also involved in NMQ transport. In Figure 7 , we illustrated the position of the amino acids mutated in this study. From this figure, it appears that the amino acids that might interact with NMQ are far apart and therefore some interactions likely are indirect or in different conformations of the enzymatic cycle.
NMQ transport activity of the second group mutants (L65A, F336A, I340A, F942A, and V982A) was not significantly different from that of the wild-type P-gp (60-150%). Although Leu 65 , Phe
942
, and Val 982 have been shown to play a role in verapamil transport (Aller et al., 2009; Loo et al., 2006a Loo et al., , 2009 ), mutation of these amino acids did not affect NMQ transport in our assay. Other studies showed that Phe 336 and Ile
340
, which did not influence NMQ transport significantly, seem to have a more indirect role in transport of substrates (Loo and Clarke, 2002a , 2002b Loo et al., 2009; Ravna et al., 2009 ) and the peptide inhibitors QZ59-RRR and QZ59-SSS bind to these amino acids in the mouse P-gp crystal structure (Aller et al., 2009) .
We only investigated the effect of amino acid mutations on DLC interaction in mutants in which NMQ transport could Fig. 7 . Position of the mutated residues in P-gp (PDB 3G5U). (A) The amino acids that are located in different P-gp TMDs have been mutated in this study. (B) The mutation of Ile306, Phe343, Phe728, Thr945, and Leu975 abolishes NMQ transport activity of P-gp that was conserved following the mutation in Leu65, Phe336, Ile340, Phe942, and Val982 (view: from cytosol to membrane). 2) of the DLCs compared with wild-type P-gp. More remarkable were the inhibitory affinities of F336A and I340A, which were significantly different in five cases. Moreover, the IC 50 ratio for cymarin, digoxin, peruvoside, and proscillaridin A was largely increased (IC 50 ratio of 2.3-4.4), whereas that of digitoxin (IC 50 ratio of 1.6-2.0) and strophanthidol (IC 50 ratio of 0.6-1.1) was hardly affected. It seems that the presence of a hydroxyl group at position 12β (present in digoxin and not in digitoxin) reduces the apparent affinity when the side chain of Phe 336 and Phe 942 is absent. Strophanthidol is the only DLC tested that has no sugar moiety (at 3β). Although the sugars (cymarose, tridigitoxose, methyl glucose, and rhamnose) have different structures, they all contain a pyranose ring and several hydroxyl groups that are sufficient for interaction with phenylalanine or isoleucine.
In conclusion, our results showed that a δ-lactone ring and a sugar moiety at 3β of the steroid body are favorable for DLC binding to P-gp. In addition, hydroxyls at 5β and 19 increase DLC inhibition, whereas those at positions 1β, 11α, 12β, and 16β decrease DLC inhibition. Although the toxicity of several DLCs is primarily due to inhibition of their therapeutic target Na,K-ATPase, interactions at the transporter level can influence their concentration at the target site. Inhibition of P-gp transport by other drugs has been shown to be an important determinant in digoxin-induced toxicity. Elucidation of the molecular mechanism of DLC translocation by P-gp will help in understanding and predicting potentially harmful drug-drug interactions and will aid in the development of DLCs that are less susceptible to pharmacokinetic interactions. We identified DLC properties that are important for their interaction with P-gp and that should be omitted in the selection of new therapeutic DLCs.
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